US 11,912,706 B2
Crystal forms of a POL1 inhibitor
Mustapha Haddach, San Diego, CA (US)
Assigned to PIMERA, INC., San Diego, CA (US)
Appl. No. 16/497,724
Filed by PIMERA, INC., San Diego, CA (US)
PCT Filed Mar. 28, 2018, PCT No. PCT/US2018/024898
§ 371(c)(1), (2) Date Sep. 25, 2019,
PCT Pub. No. WO2018/183540, PCT Pub. Date Oct. 4, 2018.
Claims priority of provisional application 62/491,635, filed on Apr. 28, 2017.
Claims priority of provisional application 62/477,746, filed on Mar. 28, 2017.
Prior Publication US 2023/0192694 A1, Jun. 22, 2023
Int. Cl. C07D 471/14 (2006.01)
CPC C07D 471/14 (2013.01) [C07B 2200/13 (2013.01)] 8 Claims
 
1. A crystalline form of Compound (I):

OG Complex Work Unit Chemistry
N-methyl-2-(4-methyl-1,4-diazepan-1-yl)benzo[4,5]imidazo[1,2-a][1,8]naphthyridine-6-carboxamide characterized by having a powder X-ray diffraction (PXRD) pattern peaks of 2-theta, at about 10.0° and 20.7°, the crystalline form being the crystalline Form 1.